Ibiglustat (L-Malic acid)
CAS No. 1629063-78-0
Ibiglustat (L-Malic acid) ( Ibiglustat L-Malic acid | Venglustat (L-Malic acid) | SAR402671 (L-Malic acid) | GZ402671 (L-Malic acid) )
产品货号. M26254 CAS No. 1629063-78-0
Ibiglustat(L-苹果酸)是一种选择性、脑渗透性、葡萄糖基神经酰胺合酶变构抑制剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥549 | 有现货 |
|
| 5MG | ¥1102 | 有现货 |
|
| 10MG | ¥1644 | 有现货 |
|
| 25MG | ¥2716 | 有现货 |
|
| 50MG | ¥4018 | 有现货 |
|
| 100MG | ¥5544 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥1264 | 有现货 |
|
生物学信息
-
产品名称Ibiglustat (L-Malic acid)
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Ibiglustat(L-苹果酸)是一种选择性、脑渗透性、葡萄糖基神经酰胺合酶变构抑制剂。
-
产品描述Ibiglustat (L-Malic acid) is a selective, brain-penetrant, and allosteric inhibitor of glucosylceramide synthase. Ibiglustat (L-Malic acid) can be used in studies about PD Parkinson’s disease, SRT in Fabry’s and Gaucher’s.(In Vitro):Ibiglustat (L-Malic acid) (1 μM) treated Fabry disease cells are close to the physiological level in untreated WT cells in GL-3 levels. Ibiglustat (L-Malic acid) prevents additional GL-3 accumulation and ameliorates the abundant GL-3 levels in FD cardiomyocytes.
-
体外实验Ibiglustat (SAR402671) (1 μM, 15 days) L-Malic acid treated Fabry disease (FD) cells are close to the physiological level in untreated WT cells in GL-3 levels, suggesting that Ibiglustat L-Malic acid can prevent additional GL-3 accumulation and could serve to ameliorate the abundant levels of this sphingolipid in FD cardiomyocytes.
-
体内实验——
-
同义词Ibiglustat L-Malic acid | Venglustat (L-Malic acid) | SAR402671 (L-Malic acid) | GZ402671 (L-Malic acid)
-
通路Metabolic Enzyme/Protease
-
靶点Transferase
-
受体tubulin polymerization
-
研究领域——
-
适应症——
化学信息
-
CAS Number1629063-78-0
-
分子量523.57
-
分子式C24H30FN3O7S
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : ≥ 100 mg/mL (191.00 mM)
-
SMILES[C@H](CC(O)=O)(C(O)=O)O.C(NC(O[C@H]1C2CCN(C1)CC2)=O)(C)(C)C=3N=C(SC3)C4=CC=C(F)C=C4
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Kalmuk J, et al. Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer. Oncotarget. 2015 Sep 15;6(27):24376-92.
产品手册
关联产品
-
SB 271046 hydrochlor...
SB 271046 盐酸盐是选择性、口服活性的 5-HT6 拮抗剂。
-
Pradigastat
Pradigastat (LCQ-908) 是一种有效的,选择性的,口服活性的二酰基甘油酰基转移酶 1 (DGAT1) 抑制剂。Pradigastat 具有抗肥胖和抗糖尿病作用。
-
CP-609754
CP-609754 显示出对法呢基转移酶的选择性抑制。
021-51111890
购物车()
sales@molnova.cn

